Correlation analysis of serum uric acid level and disease activity in patients with growth hormone-secreting pituitary adenoma
10.3760/cma.j.issn.1673-4904.2019.09.010
- VernacularTitle: 垂体生长激素瘤患者血清尿酸水平与疾病活动性的相关分析
- Author:
Fang WANG
1
;
Liyong ZHONG
Author Information
1. Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
- Publication Type:Journal Article
- Keywords:
Growth hormone-secreting pituitary adenoma;
Uric acid;
Somatomedins;
Retrospective studies
- From:
Chinese Journal of Postgraduates of Medicine
2019;42(9):808-811
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the correlation between serum uric acid level and disease activity in patients with growth hormone-secreting pituitary adenoma.
Methods:The clinical data of 76 patients with growth hormone-secreting pituitary adenoma in the Department of Endocrinology of Beijing Tiantan Hospital, Capital Medical University from 2012 to 2018 were retrospectively analyzed. The patients were divided into 4 groups according to serum uric acid quartiles with 19 cases each, uric acid <233.9 μmol/L in Q1 group, uric acid 233.9 to 275.9 μmol/L in Q2 group, uric acid 276.0 to 366.7 μmol/L in Q3 group, uric acid >366.7 μmol/L in Q4 group. The sex, age, duration of disease, height, weight and blood pressure were collected, and the body mass index (BMI) was calculated. The fasting blood glucose (FBG), glycated hemoglobin, fasting insulin (FINS), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid, basal growth hormone, insulin-like growth factor-1 (IGF-1) were examined, and the IGF-1 index and homeostasis model assessment of insulin resistance (HMOA-IR) were calculated. Pearson correlation analysis was performed to explore the correlation between serum uric acid levels and disease activity.
Results:In 76 patients, 8 cases were diagnosed with hyperuricemia, accounting for 10.5%. There were no statistical differences in sex constituent, duration of disease, systolic blood pressure, diastolic blood pressure, FBG, glycated hemoglobin, TG, TC, LDL-C, growth hormone and IGF-1 index among 4 groups (P>0.05). As uric acid level increased, age and HDL-C decreased gradually from Q1 group to Q4 group: (43.58 ± 8.95), (42.58 ± 10.89), (36.58 ± 9.79), (35.37 ± 11.51) years, (1.28 ± 0.22), (1.29 ± 0.23), (1.17 ± 0.28), (1.04 ± 0.22) mmol/L; while BMI, uric acid, IGF-1 and HOMA-IR increased gradually: (25.75 ± 2.86), (27.33 ± 3.94), (26.16 ± 2.94), (28.76 ± 3.69) kg/m2, (190.73 ± 28.80), (249.57 ± 12.00), (325.75 ± 25.61), (430.39 ± 58.41) mmol/L, (594.50 ± 222.45), (733.06 ± 212.42), (774.90 ± 287.87), (962.00 ± 323.36) μg/L, 2.09 (1.64, 2.09), 3.02 (0.94, 3.55), 3.53 (2.31, 6.48), 4.09 (2.52, 5.41), there were statistical differences (P<0.05 or <0.01). Pearson correlation analysis result showed that uric acid was positive correlation with IGF-1, IGF-1 index, HOMA-IR, TG and systolic blood pressure (r = 0.491, 0.341, 0.372, 0.240 and 0.266; P<0.01 or <0.05), and uric acid was negative correlation with HDL-C (r = -0.367, P<0.01). After adjustment for sex, age, duration of disease and BMI, uric acid was still positive correlation with IGF-1 and IGF-1 index (r = 0.352 and 0.318, P<0.01).
Conclusions:Serum uric acid level is associated with disease activity in patients with growth-hormone secreting pituitary adenoma.
